Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Phase III BRIDGE open-label, switch-over clinical trial met key objectives for safety and efficacy Final analysis confirmed substantial improvement in renal function as measured by mean annualized estimated Glomerular Filtration Rate (eGFR slope) in pat... Biopharmaceuticals Protalix BioTherapeutics, Chiesi , Fabry disease, pegunigalsidase alfa
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news